SCHEMBL3266934

SCHEMBL3266934

Cc1ccc(CNc2ccc3cc(Nc4cccnc4)ccc3n2)o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.38
NPC1 O15118 2/20 0.38
POLB P06746 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TSHR P16473 2/20 0.35
NPY5R Q15761 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
ALOX12 P18054 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
KIF11 P52732 1/20 0.34
PIK3CA P42336 1/20 0.34
MCL1 Q07820 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3266968 0.87 RAB9A (0.47) RAB9ANPC1POLBL3MBTL1TSHR
SCHEMBL3267312 0.87 POLB (0.49) RAB9ANPC1POLBL3MBTL1KDM4E
SCHEMBL3267054 0.83 MAPK14 (0.42) RAB9ANPC1TSHRNPY5RKDM4E
SCHEMBL3267116 0.82 MAPT (0.44) LMNAMAPTKIF11SMN1; SMN2
SCHEMBL2902332 0.80 RAB9A (0.39) RAB9ANPC1POLBL3MBTL1TSHR
SCHEMBL3267224 0.80 MAPT (0.40) RAB9ANPC1POLBTSHRKDM4E
SCHEMBL3267196 0.78 TRPC5 (0.46) RAB9ANPC1TSHRNPY5RKDM4E
SCHEMBL2902528 0.77 RAB9A (0.40) RAB9ANPC1POLBL3MBTL1TSHR
SCHEMBL3266446 0.76 TRPC5 (0.44) RAB9ANPC1TSHRNPY5RKDM4E
SCHEMBL3267063 0.76 NPC1 (0.43) RAB9ANPC1TSHRNPY5RLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US disclosed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP disclosed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088451-A1 QUINOLINES HTR5A, HTR1A, HTR1E RAB9A 873/4885NPC1 2108/4885POLB 4479/4885
US-20120136018-A1 QUINOLINES HTR5A, HTR1A, HTR1E RAB9A 873/4885NPC1 2108/4885POLB 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.